Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived? Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.

NCT Number	NCT06782971
Lead Sponsor	Clinical Hub for Interventional Research (CHOIR) Collaborators: Cancer Institute NSW, The University of New South Wales, Australian National University
Conditions	AML - Acute Myeloid Leukemia
Enrollment	25 participants
Start Date	2025-06-06
Primary Completion	2028-02 (estimated)
Study Completion	2030-03 (estimated)
Updated on ClinicalTrials.gov	2025-12-08